Dermata Therapeutics, Inc.

NASDAQ (USD): Dermata Therapeutics, Inc. (DRMA)

Last Price

1.44

Today's Change

+0.06 (4.34%)

Day's Change

1.30 - 1.48

Trading Volume

190,557

Overview

Market Cap

2 Million

Shares Outstanding

2 Million

Avg Volume

331,985

Avg Price (50 Days)

1.24

Avg Price (200 Days)

2.53

PE Ratio

-0.11

EPS

-13.36

Earnings Announcement

31-Mar-2025

Previous Close

1.38

Open

1.34

Day's Range

1.3 - 1.48

Year Range

1.0 - 8.655

Trading Volume

198,547

Price Change Highlight

1 Day Change

4.35%

5 Day Change

14.29%

1 Month Change

32.11%

3 Month Change

11.63%

6 Month Change

-34.25%

Ytd Change

3.60%

1 Year Change

-78.79%

3 Year Change

-99.60%

5 Year Change

-99.88%

10 Year Change

-99.88%

Max Change

-99.88%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment